What is Honeynaps?
Founded in 2015, Honeynaps specializes in the development of FDA-certified AI-driven sleep data diagnosis algorithms. The company's flagship platform, SOMNUM, serves as a comprehensive ecosystem for real-time sleep bio-signal monitoring and sophisticated disease prediction. By bridging the gap between complex bio-signal management and actionable clinical insights, Honeynaps provides medical professionals and researchers with the tools necessary to enhance patient outcomes. The firm's commitment to digital healthcare innovation positions it as a critical player in the evolution of remote patient monitoring and automated diagnostic software.
How much funding has Honeynaps raised?
Honeynaps has raised a total of $11.6M across 1 funding round:
Series B
$11.6M
Series B (2024): $11.6M with participation from Industrial Bank of Korea and Quad Investment Management
Key Investors in Honeynaps
Industrial Bank of Korea
A prominent financial institution established in 1961, specializing in providing comprehensive banking and credit solutions to small and midsized enterprises across Asia.
Quad Investment Management
An independent asset management firm overseeing significant equity assets, known for its focus on absolute return strategies and long-term partnership-driven investment models.
What's next for Honeynaps?
Following this major enterprise-level funding, Honeynaps is well-positioned to accelerate its international expansion and deepen its research and development capabilities. The strategic allocation of this capital will likely focus on scaling the SOMNUM platform's reach, enhancing the precision of its AI diagnostic models, and fostering deeper integration within global clinical workflows. As the demand for non-invasive, data-backed sleep health solutions grows, Honeynaps is poised to leverage its technological moat to capture a larger share of the digital health market, potentially setting new standards for diagnostic accuracy in sleep medicine.
See full Honeynaps company page
